Tinengotinib is under clinical development by TransThera Sciences (Nanjing) and currently in Phase II for Thyroid Cancer. According to GlobalData, Phase II drugs for Thyroid Cancer have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tinengotinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tinengotinib overview

TT-00420 is under development for the treatment of solid tumors including triple-negative breast cancer, cholangiocarcinoma, biliary tract cancer, HER2-negative breast cancer, bladder cancer, colon cancer, head and neck squamous cell carcinoma , small cell lung cancer, prostate cancer, thyroid cancer, sarcoma, gastric cancer, gallbladder cancer, hepatocellular carcinoma, metastatic or advanced renal clear cell carcinoma (RCC), metastatic or advanced urothelial carcinoma (UC) and metastatic castration-resistant prostate cancer (mCRPC). The therapeutic candidate is administered through oral route. It acts by targeting aurora kinase A and aurora kinase B.

TransThera Sciences (Nanjing) overview

TransThera Sciences (Nanjing) (TransThera Sciences) is a biotechnology company that develops innovative therapeutics to target diseases with major unmet medical needs via the internal research platform and open innovation. The company develops and commercializes small molecule therapeutic agents for cancer, cardiovascular and inflammatory diseases. It focuses on the discovery and development of highly differentiated small-molecule new drugs and serving the medical needs of patients worldwide. Its oncology product portfolio includes TT-00420, TT-00434, TT-01488, TT-009373, and TT-ROMI. Its non-oncology products are TT-00920, TT-01688, TT-01025 and TT-RIAN. TransThera Sciences is headquartered in Nanjing, Jiangsu, China.

For a complete picture of Tinengotinib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.